Predictive Modeling in Rheumatology Professors and Supervisors | ApplySharif

جست‌وجوی استاد و پژوهشگر

استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشی‌تان را پیدا کنید و با او ارتباط بگیرید.

نمایش ۴۶-۶۰ از ۵۵۴ استاد راهنما

اطلاعات این پروفایل‌ها از صفحات عمومی دانشگاه‌ها جمع‌آوری شده و ممکن است به‌روز نباشد.

Tanveer Towheedمشاهده پروفایل

استاد

Queen's University at KingstonCanada

Dr. Tanveer E. Towheed is a Professor of Medicine (Rheumatology) and Public Health Sciences at Queen's University. He graduated in medicine from Queen's in 1989 and completed a research fellowship in rheumatic disease epidemiology at the University of Maryland. His work focuses on osteoarthritis and osteoporosis management, including systematic reviews and Cochrane analyses. Notably, he contributed to the 2012 American College of Rheumatology Treatment Recommendations for hand, hip, and knee osteoarthritis. His research explores glucosamine efficacy, hand osteoarthritis therapies, and bone health interventions. Education: MD from Queen's University (1989) Research Fellowship in Rheumatic Disease Epidemiology at University of Maryland Research Interests: Medical management of osteoarthritis Clinical osteoporosis treatment Role of glucosamine in osteoarthritis Evidence-based guidelines for musculoskeletal conditions Recent Article Themes: Non-surgical therapies for hand osteoarthritis Bone loss in spondyloarthritis Fracture risk prediction models ANCA-associated vasculitis management Combination analgesic trials Awards/Grants: No explicit awards listed, but his contributions to clinical guidelines and systematic reviews reflect significant academic recognition. Labs/Teams: Involved in collaborative efforts like the Core Expert Panel for ACR osteoarthritis guidelines and the CanVasc initiative for vasculitis management.

پروفایل رسمی دانشگاه

Ren, Leiمشاهده پروفایل

استاد

University of Maryland, BaltimoreUnited States

Lei Ren, PhD is a Professor and Associate Chief of Physics Research in the Department of Radiation Oncology at the University of Maryland School of Medicine. Previously, he held faculty positions at Duke University Medical Center from 2011-2021, progressing from Assistant Professor to Professor and Director of Physics Research. A clinical medical physicist certified by the American Board of Radiology (ABR), Dr. Ren leads a research program focused on advancing precision radiation therapy through innovative imaging and AI technologies. Dr. Ren's research centers on image-guided radiation therapy (IGRT) and AI applications in radiotherapy. His seminal contributions include developing digital tomosynthesis (DTS) for fast target localization, creating the limited-angle intrafraction verification (LIVE) system, and pioneering cone-beam CT (CBCT) scatter correction methods. Current work focuses on deep learning for deformable image registration, virtual MRI/CBCT generation, XMAN phantom development, and proton dose verification using prompt gamma imaging. His research integrates biomechanical modeling with AI to improve soft tissue contrast and motion management. His 15 most recent publications (2023-2025) reveal a strong trend toward clinical translation of AI in radiation oncology, with emphasis on interpretable AI for clinical decision making, radiomics for cancer prognostics, and novel imaging techniques for proton therapy verification. Approximately 70% of recent work involves deep learning applications, while 30% focuses on advanced imaging physics for motion management and dose verification. Award highlights include: Fellow of the American Association of Physicists in Medicine (AAPM), 2020 Thomas Gorrie Clinical Leadership Impact Award, Duke University, 2019 Top 5 team in AAPM Grand Challenge for 4D-CBCT reconstruction, 2018 Multiple Excellence in Research/Mentorship awards from Duke Medical Physics Program Distinguished Graduate Award from Tsinghua University, 2003 Dr. Ren actively mentors postdoctoral fellows and has secured substantial NIH funding as Principal Investigator for projects including 3D prompt gamma imaging (R01CA279013), XMAN phantoms (R01EB032680), and hybrid virtual-MRI/CBCT systems (R01EB028324). His lab collaborates with industry partners including Varian Medical Systems and ScandiDos AB on clinical implementation of imaging technologies. He serves on NIH study sections and as Deputy Editor for Medical Physics journal. His research group operates within the Radiation Oncology Department's imaging physics division, developing clinical tools for liver SBRT, proton therapy verification, and AI-driven treatment planning. Current projects include FLASH proton therapy dosimetry and virtual clinical trials using XMAN phantoms.

پروفایل رسمی دانشگاه

Anne-Laure Fauconمشاهده پروفایل

پژوهشگر

Karolinska InstitutetSweden

Anne-Laure Faucon is a Postdoctoral Researcher in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, Stockholm. She is also a senior nephrologist specialized in clinical nephrology and renal physiology. Her current position at Karolinska Institutet began in 2022, following a postdoctoral position at Paris-Saclay University from 2020-2022. Her educational background includes: PhD in renal epidemiology, Paris-Saclay University (2017-2020) Master of sciences in epidemiology-biostatistics, Paris-Saclay University (2017) Master of sciences in renal physiology, Paris-Descartes University (2013) Specialization in Nephrology and Doctor of Medicine (2014) Residency (2009-2014) Anne-Laure's research focuses on chronic kidney disease (CKD) across its different stages, etiologies, and complications. She aims to identify modifiable risk factors and biomarkers of CKD progression, contribute to better characterization of CKD prognosis, improve risk stratification, and assess real-life clinical management associated with improved outcomes. She bridges clinical nephrology, physiology, and epidemiology-biostatistics, applying causal inference methods to large healthcare cohort and registry data including the French NephroTest and CKD-REIN cohorts, Swedish Renal Registry, Stockholm CREAtinine Measurement project, and the Swedish KIdney Pathology cohort. Her recent publications demonstrate a strong focus on kidney function metrics, CKD progression, cardiovascular complications in kidney disease, and the intersection of kidney disease with other conditions like inflammatory bowel disease and lupus nephritis. She frequently utilizes large Swedish registry data including the Stockholm CREAtinine Measurements (SCREAM) project. Anne-Laure has received notable recognition including the upcoming ERA Curatorium Award for Young Investigators – Young Nephrologist (2025) and being named a Laureate of the French National Academy of Medicine for her work in renal physiology. She currently supervises three doctoral students (Antoine Créon, Aurora Caldinelli, and Charikleia Chrysostomou) and has previously supervised several other researchers. Anne-Laure also teaches renal physiology at Karolinska Institutet since 2024, continuing her previous teaching roles at the Paris Medical School. She is part of the Cardio-renal epidemiology research group led by Juan-Jesus Carrero at Karolinska Institutet, focusing on the intersection of kidney and cardiovascular diseases.

پروفایل رسمی دانشگاه

Kevin Williamsمشاهده پروفایل

استاد

Temple UniversityUnited States

Kevin Williams, MD is a Professor in the Department of Cardiovascular Sciences at the Lewis Katz School of Medicine, Temple University, with secondary appointments in Medical Genetics and Molecular Biochemistry. He directs research at the Aging + Cardiovascular Discovery Center and serves as principal investigator for multiple NIH-funded projects. His educational credentials include: MD from Johns Hopkins University (1980) Internal Medicine Residency at University of Chicago Medical Center (1983) Clinical Endocrinology Fellowship at Yale-New Haven Hospital (1984) Metabolism Fellowship at Columbia University (1985) Dr. Williams' research revolutionized understanding of atherosclerosis through his work on LDL retention in arterial walls, establishing foundational links between basic science and clinical approaches. His laboratory investigates diabetic dyslipidemia mechanisms and insulin-signaling proteins, emphasizing that atherosclerosis causes 50% of Western deaths and 80% of diabetic cardiovascular events. Current work addresses lipid metabolism in autoimmune diseases and cancer. His 2025 publications reveal intensified focus on cardiovascular risk in lupus/dermatomyositis patients, lipid dysregulation in obesity/cancer, and novel therapeutic targets like SCD inhibition. The work spans molecular mechanisms to clinical management, with strong emphasis on translational applications for high-risk populations. Dr. Williams serves as Consulting Editor for the Journal of Clinical Investigation and on editorial boards for Arteriosclerosis, Thrombosis and Vascular Biology and Rambam Medical Journal. He holds 11 patents related to lipoprotein modification and diabetic dyslipidemia treatment. His laboratory at Temple investigates corrective strategies for postprandial lipid disposal defects in diabetes and explores membrane lipid remodeling in metabolic disease. Current NIH projects focus on early atherosclerotic disease intervention and lipid-based therapeutic approaches for high-risk cardiovascular patients.

پروفایل رسمی دانشگاه

Ann Morganمشاهده پروفایل

استاد

University of LeedsUnited Kingdom

Professor Ann Morgan is Professor of Rheumatology at the University of Leeds School of Medicine, Head of the Molecular & Personalised Medicine Group within the Leeds Institute of Cardiovascular and Metabolic Medicine, and an Honorary Consultant Rheumatologist at Leeds Teaching Hospitals NHS Trust. She leads major national and EU research consortia including MRC TARGET, UK GCA Consortium, MRC-MATURA and HELICAL ITN, focusing on vasculitis, rheumatoid arthritis and stratified medicine. Education & Qualifications: BSc Pathology (First Class Honours) – University of Leeds MBChB with Honours (distinctions in Biochemistry & Surgery; prizes in Medicine & Surgery) – University of Leeds PhD Fc-gamma receptor genetics in rheumatoid arthritis – University of Leeds FRCP – Royal College of Physicians, London Research Interests: Her work spans bench-to-bedside themes: (i) autoantibody-FcγR biology driving persistent inflammation; (ii) genetic and soluble biomarker discovery for diagnosis, prognosis and therapy stratification; (iii) multi-omics integration (genomics, transcriptomics, proteomics) to dissect vasculitis and RA pathogenesis; (iv) clinical trials and drug-repurposing programmes to reduce glucocorticoid toxicity in giant-cell arteritis and Behçet’s syndrome; and (v) development of Affimer therapeutics targeting Fcγ receptors. Recent publications (2024-2025) reveal a shift toward machine-learning-guided biomarker discovery, multi-ancestry GWAS, proteomic signatures of large-vessel vasculitis, and predictive models for biologic response in RA and Behçet’s, emphasising personalised therapy and steroid-sparing strategies. Scientific Awards & Fellowships: MRC Clinical Training Fellowship Arthritis Research UK / Academy of Medical Sciences Clinician Scientist Fellowship HEFCE Clinical Senior Lectureship Grants & Leadership: She is PI on four current grants (>£14 M) and Co-I on eight others, including NIHR BRC Drug Repurposing stream (£6.7 M), EU HELICAL ITN, MRC TARGET (£0.7 M) and MRC-MATURA (£6 M). She chairs the UK GCA Consortium and MRC TARGET Partnership, and serves on medical boards of Vasculitis UK, PMRGCAuk and Behçet’s Syndrome Society. PhD Supervision & Teaching: Programme Director for West Yorkshire NIHR Academic Clinical Lectureships in Rheumatology; Wellcome Trust N4ward PhD supervisor; has completed supervision of 7 BSc, 2 MD and 7 PhD students; currently mentoring 4 PhD students (Foy, Limumpornpetch, Brown, Duff) and four final-year medical students on ESREP projects.

پروفایل رسمی دانشگاه

Lin Liuمشاهده پروفایل

دانشیار مدعو

University of California, San DiegoUnited States

Dr. Lin Liu is an Associate Adjunct Professor in the Department of Family Medicine and Public Health at the Herbert Wertheim School of Public Health & Human Longevity Science, UC San Diego. Her research focuses on biostatistical methodologies, including dose-response analysis, longitudinal HIV data modeling, and colorectal cancer prognostic modeling. She collaborates on studies addressing cancer, cardiovascular disease, hepatitis C, chronic pain, HIV/AIDS, and telemedicine. Dr. Liu’s work spans epidemiology, health services research, and clinical trial design. Her research interests include statistical methods for detecting minimum effective doses in toxicity studies, HIV viral load analysis, and predictive models for cancer recurrence. She has contributed to studies on opioid use, tuberculosis treatment adherence, and yoga interventions for chronic pain. Dr. Liu’s publications reflect her expertise in applying statistical techniques to public health challenges, such as improving cancer screening strategies and evaluating telehealth outcomes for mental health conditions like PTSD. Notable contributions include developing prognostic models for colorectal neoplasia recurrence and investigating the efficacy of videoconferencing psychotherapy. Her interdisciplinary collaborations span infectious disease epidemiology, psychiatric disorders, and biomedical informatics, emphasizing patient-centered care and electronic health record optimization.

پروفایل رسمی دانشگاه

Serge Ferrariمشاهده پروفایل

استاد

University of GenevaSwitzerland

Serge Ferrari is Full Professor at the University of Geneva's Faculty of Medicine , where he serves as Vice-Dean for Translational Research and Development. He concurrently heads the Division of Bone Diseases at Geneva University Hospitals (HUG) and directs the Bone Diseases Research Laboratory. His academic trajectory includes an MD from Geneva (1991), internal medicine specialization (1997), a research fellowship at Harvard Medical School (1997-2001), and progressive appointments culminating in his full professorship in 2014. From 2019-2023, he was Academic Director of the Department of Medicine. His research explores biological mechanisms of bone remodeling and therapeutic targets for bone fragility , with continuous SNSF funding for over 20 years. Primary interests include osteoporosis pathophysiology, genetic determinants of bone strength, and translational applications in metabolic bone diseases. Current work emphasizes diabetes-related skeletal fragility and optimization of anti-osteoporosis drug sequences. Analysis of 15 recent publications (2025-2024) reveals dominant themes: osteoporosis pharmacotherapy (romosozumab, denosumab), fracture risk modeling , diabetic bone disease , and treatment guidelines . Articles frequently utilize advanced metrics like trabecular bone score (TBS) and 3D bone modeling, reflecting methodological innovation in assessing skeletal health. Scientific Awards: SNSF Professorship (2001) He leads the Bone Diseases Research Laboratory and Osteoporosis Genetics Research Group , fostering collaborations across translational research pipelines. As Vice-Chairman of the International Osteoporosis Foundation Scientific Council (2016-2024) and former President of the Swiss Osteoporosis Association, he shapes global osteoporosis management strategies. His editorial leadership includes former roles at BoneKey and BoneKey Reports .

پروفایل رسمی دانشگاه

Andrew Craigمشاهده پروفایل

دانشیار

Queen's University at KingstonCanada

Dr. Andrew Craig is an Associate Professor in the Department of Biomedical and Molecular Sciences at Queen's University, affiliated with the Faculty of Health Sciences and the Queen’s Cancer Research Institute. He holds cross appointments in the Cancer Biology & Genetics division and the Translational Institute of Medicine (TIME). He earned his PhD in Biochemistry from McGill University (1998) and completed postdoctoral training at Queen's University before joining the faculty in 2002. His research focuses on molecular mechanisms of cancer progression, immune suppression, and metastasis, with a particular emphasis on tumor suppressor miRNAs, actin-driven metastasis, and immunotherapy strategies. Education: PhD in Biochemistry, McGill University (1998) BSc in Biochemistry, Queen's University (1993) Research Interests: Dr. Craig’s work spans immunology, oncology, and cellular biology. Key areas include: Inflammatory mechanisms and inflammasomes Cancer immunotherapy and metastasis TGF-β signaling pathways MicroRNA biomarkers in lung cancer Actin-targeting compounds for cancer treatment Research Highlights: His lab has developed novel synthetic antibodies targeting TGF-β to improve chemotherapy efficacy in ovarian cancer models. Recent studies focus on functional genomic screening to identify vulnerabilities in inflammatory breast cancer and defining miRNA biomarkers in immunotherapy-treated patients. His work integrates advanced techniques like confocal microscopy and flow cytometry. Awards: Canadian Cancer Society Young Investigator Award (2011) Grants & Funding: Dr. Craig maintains continuous external funding for his research, supported by grants from agencies such as the Canadian Cancer Society and the Canadian Institutes of Health Research (CIHR). Labs & Affiliations: He leads the Craig Lab within the Department of Biomedical and Molecular Sciences and collaborates with the Queen’s Cancer Research Institute and Translational Institute of Medicine (TIME). His research bridges basic science and clinical translation, emphasizing preclinical models of disease and precision medicine approaches.

پروفایل رسمی دانشگاه

Carolyn Bramanteمشاهده پروفایل

استادیار

University of Minnesota Twin CitiesUnited States

Carolyn Bramante, MD, MPH, serves as an Assistant Professor of Medicine within the Division of General Internal Medicine at the University of Minnesota Medical School. Clinically active in both the Adult and Pediatric Weight Management Clinics, she specializes in evidence-based obesity treatment across the lifespan while maintaining a robust research portfolio focused on pandemic-related health outcomes. Dr. Bramante's research program centers on three interconnected domains: obesity medicine (particularly pediatric/adolescent interventions), Long COVID pathophysiology, and health equity. Her work examines metabolic consequences of SARS-CoV-2 infection, weight trajectory disruptions in children post-COVID, and disparities in obesity care access. She employs advanced methodologies including target trial emulation, machine learning, and large-scale EHR analysis through the National COVID Cohort Collaborative (N3C). Analysis of her recent publications reveals a dominant focus on Long COVID prevention and treatment, with landmark contributions to the ACTIV-6 and COVID-OUT clinical trials testing metformin's efficacy. Her research consistently integrates metabolic health perspectives, demonstrating how obesity and diabetes modify COVID-19 outcomes while identifying therapeutic opportunities through drug repurposing. Methodologically, she pioneers approaches for analyzing complex real-world data to address critical questions in pandemic medicine. Dr. Bramante actively collaborates within major national research infrastructures including the N3C, ACTIV-6, and RECOVER initiatives. Her work bridges clinical practice in weight management with epidemiological research, particularly through analyses of gut barrier integrity biomarkers, rural-urban mortality disparities in autoimmune conditions, and data model enhancements for multicenter studies. Current efforts focus on predictive modeling for Long COVID risk stratification and optimizing hybrid care delivery models for underserved populations.

پروفایل رسمی دانشگاه

Lazaros Belbasisمشاهده پروفایل

پژوهشگر ارشد

Stanford UniversityUnited States

Dr Lazaros Belbasis is an Intermediate Transition Research Fellow at the Nuffield Department of Population Health, University of Oxford, a position funded by the Oxford British Heart Foundation Centre of Research Excellence since August 2024. Previously, he held an Oxford Population Health Early Career Research Fellowship starting in August 2022. He is also a research member of Kellogg College and actively contributes to undergraduate and postgraduate teaching within the department. His educational background includes a medical degree (2015) and PhD in Epidemiology (2020) from the University of Ioannina, complemented by clinical training as a General Practitioner and family medicine physician in Greece (Certificate of Completion of Training, 2021). Belbasis specializes in neuroepidemiology and causal inference methodologies, with primary research focusing on Mendelian randomization applications to identify molecular pathways in neurological disorders. His work integrates multi-omics data from population biobanks to investigate neurodegenerative diseases (Alzheimer's, Multiple Sclerosis, Parkinson's), stroke mechanisms, and environmental risk factors across diverse conditions. He maintains a strong secondary focus on meta-research, particularly umbrella reviews, prediction model reproducibility, and research integrity frameworks. Analysis of his publication record reveals consistent methodological innovation in evidence synthesis techniques, with increasing emphasis on proteomic and transcriptomic data integration since 2022. His research spans neurodegenerative disorders, cardiovascular epidemiology, respiratory diseases, and meta-epidemiological methodology development. His scientific recognition includes: PhD scholarship by Greek State Scholarships Foundation Research Fellowship by Hellenic Academy of Neuro-immunology Associate Fellowship of the Advance Higher Education Oxford Population Health Teaching Award 2024 Reviewer’s Choice Award at the 2023 American Society of Human Genetics Annual Meeting Current research is supported by the Oxford British Heart Foundation Centre of Research Excellence fellowship, building on prior funding from Greek State Scholarships Foundation and Hellenic Academy of Neuro-immunology. While he actively mentors students in teaching capacities, no formal PhD advisees are documented. His collaborative work extends to the Meta-research Innovation Center – Berlin and METRICS on evidence synthesis projects. He operates within the Nuffield Department of Population Health's research ecosystem, collaborating with the QUEST Center for Responsible Research at Charité on meta-research initiatives while maintaining active involvement in the Oxford Population Health research group.

پروفایل رسمی دانشگاه

Ira Kurtzمشاهده پروفایل

استاد

University of California, Los AngelesUnited States

Dr. Ira Kurtz is a Professor of Medicine at the University of California, Los Angeles (UCLA), and Chief of Nephrology. He is also a Member of the Brain Research Institute. His research focuses on renal physiology, acid-base homeostasis, and molecular transport mechanisms, particularly within the SLC4 transporter family. His work spans structural biology, molecular dynamics, and clinical nephrology. His scientific contributions include structural characterization of SLC4 transporters using cryo-EM and molecular dynamics simulations, revealing key insights into ion translocation pathways and conformational dynamics. He has extensively studied the molecular basis of proximal renal tubular acidosis and electrolyte disorders, with particular emphasis on NBCe1 transporter function and regulation. Dr. Kurtz's publications demonstrate expertise in renal acid-base physiology, membrane transporter characterization, and clinical applications. His work connects fundamental molecular mechanisms with human diseases, including corneal endothelial dystrophies, thrombotic microangiopathy from anti-VEGF treatments, and genetic disorders affecting ion transport. His research methodology integrates computational biology, structural biology, and translational medicine approaches. He has developed novel quantitative models for acid-base analysis and electrolyte disorders, challenging established paradigms like the Stewart approach through critical evaluation of bicarbonate-centered models.

پروفایل رسمی دانشگاه

Manuela Zucknickمشاهده پروفایل

استاد

University of OsloNorway

Statistical learning for translational cancer research
Personalized cancer therapies
Multi-omics data integration
+۷ مورد دیگر

Manuela Zucknick is Professor and Director of the Oslo Centre for Biostatistics and Epidemiology at the University of Oslo's Faculty of Medicine, Department of Biostatistics. Her research integrates statistical learning with translational cancer research to advance personalized medicine through multi-omics data integration. PhD Biostatistics, Imperial College London (2008) MSc Bioinformatics, Imperial College London (2004) Diplom Statistik, University of Dortmund (2003) Her research focuses on Bayesian methods for integrating heterogeneous data sources in cancer research, particularly for drug response prediction in pharmacogenomic screens and patient prognosis. She develops structured high-dimensional regression models for 'large p, small n' problems in molecular medicine, with emphasis on incorporating prior biological knowledge into risk prediction frameworks. Her work bridges statistical methodology with clinical applications in personalized cancer therapies. Her recent publications demonstrate consistent contributions to multi-omics integration and survival modeling across diverse clinical contexts including cancer, pregnancy complications, and rheumatoid arthritis. The research shows strong methodological innovation in handling high-dimensional biological data while maintaining clinical relevance. Through the Oslo Centre for Biostatistics and Epidemiology, she leads collaborative projects spanning oncology, obstetrics, and rheumatology. Her work frequently involves designing statistical frameworks for pharmacogenomic screens and developing tools for biomarker discovery in complex disease settings.

پروفایل رسمی دانشگاه

Jos Runhaarمشاهده پروفایل

استادیار

Erasmus University RotterdamNetherlands

Dr. Jos Runhaar is an Assistant Professor at the Department of General Practice, Erasmus MC, Rotterdam, Netherlands. He is a leading researcher in the field of musculoskeletal diseases, with a primary focus on the prevention and early diagnosis of osteoarthritis. He leads a dynamic research group involving 12 PhD students, research assistants, and clinician-researchers, and maintains a strong national and international scientific network. His research interests center on improving the management of musculoskeletal disorders in primary care settings, particularly among general practitioners and physiotherapists. He aims to shift treatment paradigms toward earlier intervention and primary prevention of osteoarthritis. His work integrates epidemiological methods, clinical diagnostics, and patient-centered outcomes to enhance early detection and effective conservative management. The recent publications highlight a strong trend in clinical and epidemiological research on osteoarthritis, with specific emphasis on knee and hip osteoarthritis, causal relationships (e.g., obesity and OA), exercise interventions, patient preferences, and imaging-based risk prediction. His research employs advanced methodologies such as Mendelian randomization, causal mediation analysis, discrete choice experiments, and large-scale meta-analyses. Dr. Runhaar has been recognized with several prestigious scientific awards, including: Rising Star Award for Clinical Research (OARSI, 2023) FOREUM Clinical Research Award (2022) European League Against Rheumatology Training Bursary (2018) Honorary Research Fellow (2018) ISMRM Trainee Stipend (2017) IWOAI Young Investigator Award (2017) He has secured over €1.5 million in research funding as principal applicant from major organizations such as ZonMw, EULAR, ISAKOS, OARSI, and the Dutch Arthritis Society. He actively supervises multiple PhD students and contributes to academic governance through roles on scientific committees including OARSI’s Research & Training Committee (Chair), Ethics & Governance Committee, and the Scientific Advisory Board for the Dutch Arthritis Society. He also participates in international thesis assessment committees. Dr. Runhaar’s research is conducted within a collaborative framework involving multiple institutions, as evidenced by his involvement in the World COACH consortium and other international networks. His group focuses on translating research findings into clinical practice in primary care and rehabilitation settings.

پروفایل رسمی دانشگاه

Veronika Gjertsen Rypdalمشاهده پروفایل

پژوهشگر

UiT The Arctic University of NorwayNorway

Veronika Gjertsen Rypdal is a researcher at UiT The Arctic University of Norway, Faculty of Health Sciences, Department of Clinical Medicine. She is an active contributor to the Nordic Juvenile Idiopathic Arthritis (JIA) cohort study, a population-based multicenter research initiative spanning Norway, Sweden, Denmark, and Finland that has followed JIA patients since 1997. Her research focuses on long-term outcomes in juvenile idiopathic arthritis, with particular emphasis on disease activity trajectories from childhood to adulthood, predictive modeling of unfavorable outcomes, and specialized areas including uveitis, orofacial manifestations, and quality-of-life assessments in JIA patients. Dr. Rypdal completed her doctoral thesis in 2021 titled 'Prediction of unfavorable outcome in Juvenile Idiopathic Arthritis (JIA) and assessment of the long-term outcomes in JIA-associated uveitis.' Analysis of her publication record reveals a strong focus on longitudinal population-based studies, with recent work examining BMI associations with JIA outcomes, fatigue in young adults with JIA, and inflammatory biomarkers predicting disease remission. Her research consistently employs rigorous methodology including prospective cohort designs, multicenter collaboration, and clinically relevant outcome measures. Dr. Rypdal collaborates extensively with leading Nordic researchers in pediatric rheumatology, contributing to major publications in high-impact rheumatology journals. Her work has significant clinical implications for early treatment decisions and personalized management approaches in juvenile arthritis.

پروفایل رسمی دانشگاه

Mark Scheperمشاهده پروفایل

استاد

Rotterdam University of Applied SciencesNetherlands

Mark Scheper is a Professor at Macquarie University (Faculty of Medicine and Health Sciences) and Lecturer at Rotterdam University of Applied Sciences in the field of AI & Data-Supported Healthcare. He serves as Science Lead at HR Datalab Healthcare and co-founded the National Expertise Center for Ehlers-Danlos Syndrome at Erasmus MC. PhD in Pediatric Rare Diseases (University of Amsterdam, 2019) Specialist in Ehlers-Danlos syndrome and chronic fatigue Expert in ethical AI and data science for healthcare His research focuses on integrating artificial intelligence into clinical practice while addressing ethical implications and workforce readiness. He leads transdisciplinary projects like ACT4FATIGUE (chronic fatigue prediction) and Orange Babies (sports performance optimization), emphasizing responsible AI adoption. Recent publications analyze trends in digital healthcare ethics , AI-assisted diagnostics , and chronic pediatric conditions . His work spans from rare diseases in children to sports injury prevention, with particular attention to data quality and technology accessibility. Collaborates with Medical Delta, Health Holland, and national medical centers Develops learning communities through co-creation with professionals, patients, and policymakers Focuses on training healthcare workers for AI literacy and ethical deployment

پروفایل رسمی دانشگاه